Payment overview · 2025
General Payments
$1,074.26
19 reported records · 4 companies
Healthcare provider profile · identity verified
Dennis Malate Redubla
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CLOVIS, CA · NPI 1053633206
Verified facts
What the public records show
CMS Open Payments records show Dennis Malate Redubla received $1,074.26 in general payments during 2025 across 19 reported records.
Surgenex LLC accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Surgenex LLC | Unresolved — no canonical attribution shown | $467.61 | 43.5% | 11 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $340.30 | 31.7% | 6 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $141.36 | 13.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.99 | 11.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,074.26 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $467.61 | 11 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $467.61 | 11 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $467.61 | 11 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $467.61 | 11 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $467.61 | 11 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $340.30 | 6 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $141.36 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 34 |
| Omeprazole | Omeprazole | 214 | 25 |
| Metformin Hcl | Metformin Hcl | 196 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 180 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 25 |
| Furosemide | Furosemide | 157 | 23 |
| Lisinopril | Lisinopril | 154 | 22 |
| Risperidone | Risperidone | 135 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 109 | 15 |
| Famotidine | Famotidine | 106 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 11 |
| Gabapentin | Gabapentin | 96 | 14 |
| Levetiracetam | Levetiracetam | 96 | 15 |
| Sertraline Hcl | Sertraline Hcl | 87 | suppressed |
| Lorazepam | Lorazepam | 85 | 27 |
| Olanzapine | Olanzapine | 82 | 11 |
| Trazodone Hcl | Trazodone Hcl | 80 | 18 |
| Lactulose | Lactulose | 78 | 15 |
| Allopurinol | Allopurinol | 76 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | suppressed |
| Carvedilol | Carvedilol | 72 | suppressed |
| Phenobarbital | Phenobarbital | 71 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 67 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 63 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | suppressed |
| Aripiprazole | Aripiprazole | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 57 | suppressed |
| Losartan Potassium | Losartan Potassium | 56 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 53 | suppressed |
| Eliquis | Apixaban | 49 | suppressed |
| Lamotrigine | Lamotrigine | 49 | suppressed |
| Lacosamide | Lacosamide | 48 | suppressed |
| Linzess | Linaclotide | 48 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 39 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 30 |
| Carbamazepine | Carbamazepine | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Nystop | Nystatin | 23 | suppressed |
| Clarithromycin | Clarithromycin | 22 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Prednisone | Prednisone | 12 | 11 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,074.26 · 19 records | Surgenex LLC | ArdeoGraft, BREZTRI, FANAPT, NUVISION ICE CATHETER, PelloGraft, RenoGraft, SurGraft, SurMatrix | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error